

# CITATION REPORT

List of articles citing

## Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

DOI: 10.3389/fpubh.2021.628744

Frontiers in Public Health, 2021, 9, 628744.

**Source:** <https://exaly.com/paper-pdf/80010634/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Childhood cancer medicines: understanding barriers to access. <i>The Lancet Global Health</i> , <b>2021</b> , 9, e1195-e1196	3.16	0
16	Pharmacies in informal settlements: a retrospective, cross-sectional household and health facility survey in four countries. <i>BMC Health Services Research</i> , <b>2021</b> , 21, 945	2.9	1
15	Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 743558	6	0
14	National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1003944	11.6	0
13	Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 42, 1-7	7.1	
12	Phytotherapy in Integrative Oncology: An Update of Promising Treatment Options. <i>Molecules</i> , <b>2022</b> , 27, 3209	4.8	0
11	price-variation-among-registered-brands-of-anti-cancer-medicines-available-in-pakistan. <b>2022</b> , 8, 42-56		0
10	Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda.		0
9	Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. 10,		1
8	Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. 13,		1
7	How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?. <b>2022</b> ,		1
6	Chemotherapy supply chain management, safe-handling and disposal in Ethiopia: the case of Tikur Anbessa specialized hospital. 1-9		0
5	Barriers in access to oncology drugs: a global crisis.		0
4	The health system and access to treatment in patients with cervical cancer in Mexico. 12,		0
3	Substantial Increase in Accessibility to Essential Anticancer Medicines in Anhui, China: A Longitudinal Study. <b>2023</b> , 60, 004695802311517		0
2	Activities against Lung Cancer of Biosynthesized Silver Nanoparticles: A Review. <b>2023</b> , 11, 389		0
1	Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria. 11,		0

